Kymera Therapeutics develops targeted protein degradation medicines for immunological diseases as a clinical-stage biopharmaceutical company. News about KYMR commonly centers on oral small molecule degrader programs, including KT-621, a STAT6 degrader for Type 2 inflammatory diseases such as atopic dermatitis and asthma, and KT-579, an IRF5 degrader tied to inflammatory bowel disease biology.
Company updates also cover preclinical and clinical data presentations, FDA regulatory designations, collaboration activity involving degrader candidates such as KT-200, and periodic operating and financial results. Additional announcements include investor conference participation and shareholder voting matters.
Kymera Therapeutics (NASDAQ: KYMR) will participate in three investor fireside chats in early December 2025: Piper Sandler 37th Annual Healthcare Conference in New York on Dec 2 at 2:30 p.m. ET, Citi 2025 Global Healthcare Conference in Miami on Dec 3 at 11:15 a.m. ET, and Evercore 8th Annual Healthcare Conference in Coral Gables on Dec 4 at 8:45 a.m. ET. Live webcasts and archived replays will be available in the Investors "News and Events" section at www.kymeratx.com.
Kymera Therapeutics (NASDAQ: KYMR) reported third-quarter 2025 results and pipeline progress. Key financials include cash of $978.7 million as of September 30, 2025, and an expected cash runway into the second half of 2028. The company posted a net loss of $82.2 million with R&D expense of $74.1 million in Q3.
Clinical highlights: KT-621 completed enrollment and dosing in the BroADen Phase 1b atopic dermatitis study with data expected in December 2025, initiated the BROADEN2 Phase 2b in AD, and is on track to start the BREADTH Phase 2b asthma trial in 1Q 2026. KT-579 completed IND-enabling studies with Phase 1 expected in early 2026.
Kymera Therapeutics (NASDAQ: KYMR) will participate in multiple investor fireside chats in November 2025. Events and times: Guggenheim Healthcare Innovation in Boston on Nov 10, 9:00 AM ET; UBS 2025 Global Healthcare in Palm Beach on Nov 10, 11:45 AM ET; Stifel 2025 Healthcare in New York on Nov 11, 1:20 PM ET; TD Cowen Virtual Immunology & Inflammation Summit on Nov 13, 10:30 AM ET; and Jefferies Global Healthcare in London on Nov 19, 11:00 AM GMT.
Live webcasts and replay archives will be available under News and Events in the Investors section of the company's website at www.kymeratx.com.
Kymera Therapeutics (NASDAQ: KYMR) will report third quarter 2025 financial results on November 4, 2025.
The company will host a video conference call and livestreamed webcast on November 4, 2025 at 8:30 a.m. ET. Investors can register to join the video call or view the webcast via the company’s Investors > News and Events page at www.kymeratx.com. A replay of the webcast will be archived and available after the event.
Kymera Therapeutics (NASDAQ: KYMR) presented new preclinical data for KT-579, an oral IRF5 degrader, at the American College of Rheumatology Annual Meeting on Oct 27, 2025. The data show disease‑modifying activity across multiple lupus and rheumatoid arthritis models, including reductions in blood interferon‑stimulated genes, serum anti‑dsDNA autoantibodies, kidney IgG deposition, and protection from renal disease progression in lupus models, plus dose‑dependent joint swelling reduction and bone‑protection in RA models. In vitro human assays showed blockade of Th1‑skewing cytokines. The company intends to initiate Phase 1 testing in early 2026.
Kymera Therapeutics (NASDAQ: KYMR) announced late-breaking presentations of positive Phase 1 results for KT-621, their first-in-class oral STAT6 degrader, at two major medical conferences. The Phase 1 healthy volunteer trial demonstrated that KT-621 achieved >90% STAT6 degradation in blood at doses above 1.5 mg and complete degradation in both blood and skin at doses ≥50 mg.
The drug showed impressive biomarker results comparable or superior to dupilumab, with TARC reduction up to 37% and Eotaxin-3 reduction up to 63%. KT-621's BroADen Phase 1b trial in atopic dermatitis patients will report data in Q4 2025, followed by Phase 2b trials in AD and asthma initiating in Q4 2025 and Q1 2026, respectively.
Kymera Therapeutics (NASDAQ: KYMR), a clinical-stage biopharmaceutical company focused on developing oral small molecule degrader medicines, has appointed Brian Adams as Chief Legal Officer and Corporate Secretary. Adams brings nearly two decades of life sciences leadership experience and will oversee the company's legal, governance, and intellectual property functions.
Adams joins from Relay Therapeutics where he served as Chief Legal Officer. His previous experience includes senior roles at Keryx Biopharmaceuticals, Algeta ASA, AVEO Oncology, and Genzyme Corporation. He succeeds Ellen Chiniara, who is retiring to focus on board service and advisory opportunities.
Kymera Therapeutics (NASDAQ: KYMR), a clinical-stage biopharmaceutical company focused on developing oral small molecule degrader medicines for immunological diseases, has announced its participation in four major investor conferences in September 2025.
The company will engage in fireside chats at the Citi Biopharma Back to School Conference (Sept 3), Wells Fargo Healthcare Conference (Sept 4), Morgan Stanley Global Healthcare Conference (Sept 9), and Stifel Virtual Immunology and Inflammation Forum (Sept 15). All presentations will be accessible via live webcast on the company's website, with replays available afterward.
Kymera Therapeutics (NASDAQ: KYMR) reported significant Q2 2025 financial results and pipeline progress. The company announced positive Phase 1 data for KT-621, their oral STAT6 degrader, demonstrating complete STAT6 degradation and favorable safety profile. Kymera secured a strategic partnership with Gilead worth up to $750 million for CDK2 degrader development.
Financial highlights include a strong cash position of $1 billion as of July 31, 2025, extending runway into H2 2028. Q2 2025 showed collaboration revenues of $11.5 million and a net loss of $76.6 million. The company completed a $288 million equity offering in June 2025.
Pipeline developments include advancing KT-621 to Phase 2b trials in atopic dermatitis and asthma starting Q4 2025 and Q1 2026, respectively. KT-579, their IRF5 degrader, is progressing toward Phase 1 trials in early 2026.
Kymera Therapeutics (NASDAQ: KYMR), a clinical-stage biopharmaceutical company focused on developing oral small molecule degrader medicines for immunological diseases, has scheduled its second quarter 2025 financial results announcement for August 11, 2025.
The company will host a video conference call and webcast at 8:30 a.m. ET on the same day. Interested parties can register for the video call and access the webcast through a provided link or by visiting the "News and Events" section in the Investors area of Kymera's website.